Edesa Biotech Inc.   Report issue

For profit Phase 2
Founded: Markham Canada (2015)

Organization Overview

First Clinical Trial
2018
NCT03680131
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Edesa Biotech Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

eb01 (1 trial)

eb05 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Allergic Contact (Phase 2)

Dermatitis, Contact (Phase 2)

Pneumonia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2